Graviton Biosciences, a NYC-based biotechnology company, raised an undisclosed amount in funding.
Enavate Sciences, a portfolio company of Patient Square Capital, made the investment.
The company intends to use the funds to advance clinical development of GV101 and its pipeline of ROCK2 inhibitors to treat a range of serious fibrotic, inflammatory and neurologic conditions.
Led by Samuel Waksal, Ph.D., CEO and Founder, Graviton Bioscience is a clinical stage drug discovery and development company, dedicated to engineering and developing therapeutics for treating CNS, autoimmune, fibrotic and other serious diseases where ROCK2 plays a pivotal role in pathology. Its first drug candidate GV101 is in clinical studies, with additional assets advancing through the preclinical pipeline. ROCK2 is an effector of the small GTPase Rho and belongs to the AGC family of kinases. It is implicated in the pathology of multiple diseases, including metabolic, autoimmune, inflammatory and neurologic disorders for which there is either inadequate or no treatment at all. Graviton’s team previously pioneered the development of Rezurock®, the first approved ROCK2 inhibitor, for graft vs. host disease.
The funding represents the eighth portfolio investment Enavate has made in partner companies to date and follows Ovid Therapeutics’ investment as part of a collaboration with Graviton announced in May 2023.
FinSMEs
03/01/2024